A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis

Archives of Dermatology

Volumn 143, Issue 4, 2007, Pages 463-470

  Thornhill, Martin H ^a   Baccaglini, Lorena ^c   Theaker, Elizabeth ^b   Pemberton, Michael N ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY DENTAL HOSPITAL OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO;

APHTHOUS STOMATITIS; APPETITE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FLUSHING; FOLLOW UP; HALLUCINATION; HEADACHE; HEART RATE; HUMAN; MEDICAL SPECIALIST; MOTION SICKNESS; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; SIDE EFFECT; STOMACH DISCOMFORT; SYNCOPE; TREATMENT RESPONSE; ULCER;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PENTOXIFYLLINE; RECURRENCE; STOMATITIS, APHTHOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247332148     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.4.463     Document Type: Article

References (57)

1. Axell T, Henricsson V. The occurrence of recurrent aphthous ulcers in an adult Swedish population. Acta Odontol Scand. 1985;43:121-125.
2. Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. Crit Rev Oral Biol Med. 1998;9:306-321.
3. Lehner T. Pathology of recurrent oral ulceration and oral ulceration in Behcet's syndrome: light, electron and fluorescence microscopy. J Pathol. 1969;97:481-494.
4. Bagan JV, Sanchis JM, Milian MA, Penarrocha M, Silvestre FJ. Recurrent aphthous stomatitis: a study of the clinical characteristics of lesions in 93 cases. J Oral Pathol Med. 1991;20:395-397.
5. Muzyka BC, Glick M. Major aphthous ulcers in patients with HIV disease. Oral Surg Oral Med Oral Pathol. 1994;77:116-120.
6. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of the Behcet's type: successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol. 1987;64:289-292.
7. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol. 1985;12:85-90.
8. Grinspan D, Blanco GF, Aguero S. Treatment of aphthae with thalidomide. J Am Acad Dermatol. 1989;20:1060-1063.
9. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf. 1992;7:116-134.
10. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1979;115:636-637.
11. Nicolau DP, West TE. Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. DICP. 1990;24:1054-1056.
12. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923-927.
13. Yasui K, Kobayashi N, Yamazaki T, Agematsu K. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005;11:395-401.
14. Gatot A, Tovi F. Colchicine therapy in recurrent oral ulcers [letter]. Arch Dermatol. 1984;120:994.
15. Katz J, Langevitz P, Shemer J, Barak S, Livneh A. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol. 1994;31:459-461.
16. Ruah CB, Stram JR, Chasin WD. Treatment of severe recurrent aphthous stomatitis with colchicine. Arch Otolaryngol Head Neck Surg. 1988;114:671-675.
17. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252-256.
18. Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-α mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol. 1995;25:2899-2906.
19. Dunzendorfer S, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Pentoxifylline differentially regulates migration and respiratory burst activity of the neutrophil. Ann N Y Acad Sci. 1997;832:330-340.
20. Pizarro A, Navarro A, Fonseca E, Vidaurrazaga C, Herranz P. Treatment of recurrent aphthous stomatitis with pentoxifylline. Br J Dermatol. 1995;133:659-660.
21. Pizarro A, Herranz P, Ferrer M, Casado M. Recurrent oral aphthosis: treatment with pentoxifylline [in Spanish] [letter]. Med Clin (Barc). 1993;101:237.
22. Pizarro A, Navarro A. The treatment of a case of recurrent oral aphthosis with pentoxifylline. Rev Clin Esp. 1993;192:96-97.
23. Wahba-Yahav AV. Pentoxifylline in intractable recurrent aphthous stomatitis: an open trial. J Am Acad Dermatol. 1995;33:680-682.
24. Wahba-Yahav AV. Severe idiopathic recurrent aphthous stomatitis: treatment with pentoxifylline [letter]. Acta Derm Venereol. 1995;75:157.
25. Chandrasekhar J, Liem AA, Cox NH, Paterson AW. Oxypentifylline in the management of recurrent aphthous oral ulcers: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:564-567.
26. Santos J, Marquez M, Rivero A, Salgado F. Pentoxifylline in patients with AIDS and oral aphthous ulcers [letter] [in Spanish]. Med Clin (Barc). 1994;102:519.
27. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med. 1996;124:891-893.
28. Samlaska CP, Winfield EA. Pentoxifylline. J AmAcad Dermatol. 1994;30:603-621.
29. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97.
30. Schwarz A, Krone C, Trautinger F, et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol. 1993;101:549-552.
31. Schwarz T, Schwarz A, Krone C, Luger TA. Pentoxifylline suppresses allergic patch test reactions in humans. Arch Dermatol. 1993;129:513-514.
32. Dubost JJ, Soubrier M, Ristori JM, et al. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev Rhum Engl Ed. 1997;64:789-793.
33. Kiely PD, Johnson D, Bourke BE. An open study of oxpentifylline in early rheumatoid arthritis. Br J Rheumatol. 1998;37:1033-1035.
34. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol. 1995;22:625-629.
35. Friedman JE, Zabriskie J, Bourganskaia E. A pilot study of pentoxifylline in multiple sclerosis. Arch Neurol. 1996;53:956-957.
36. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996;64:193-200.
37. van Oosten BW, Rep MH, van Lier RA, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol. 1996;66:49-55.
38. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159:508-511.
39. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
40. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology. 1993;187:447-463.
41. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNFα, IL-1β, IL-6, IL-8, TNFβ, and IL-10 by pentoxifylline. Int J Immunopharmacol. 1996;18:739-748.
42. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology. 1994;83:262-267.
43. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol. 1993;23:1745-1751.
44. Tilg H, Eibl B, Pichl M, et al. Immune response modulation by pentoxifylline in vitro. Transplantation. 1993;56:196-201.
45. Dominguez-Jimenez C, Sancho D, Nieto M, et al. Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol. 2002;71:588-596.
46. Bratel J, Hakeberg M, Jontell M. The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial. Oral Health Prev Dent. 2005;3:3-8.
47. Drinnan AJ, Fischman SL. Randomized, double-blind study of levamisole in recurrent aphthous stomatitis. J Oral Pathol. 1978;7:414-417.
48. Miller MF, Silvert ME, Laster LL, Green P, Ship II. Effect of levamisole on the incidence and prevalence of recurrent aphthous stomatitis: a double-blind clinical trial. J Oral Pathol. 1978;7:387-392.
49. Grassin M, Brochet B, Coussemacq M, Brochet H. Controlled therapeutic trials of pentoxifylline in relapsing-experimental auto-immune encephalomyelitis. Acta Neurol Scand. 1998;97:404-408.
50. Myers LW, Ellison GW, Merrill JE, et al. Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase. Neurology. 1998;51:1483-1486.
51. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood. 1993;82:732-736.
52. Ferra C, de Sanjose S, Lastra CF, et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant. 1997;20:1075-1080.
53. Stockschlader M, Kalhs P, Peters S, et al. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:357-362.
54. van der Jagt RH, Pari G, McDiarmid SA, Boisvert DM, Huebsch LB. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1994;13:203-207.
55. Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:36-42.
56. Zeni F, Pain P, Vindimian M, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patientswith septic shock: results from a doubleblind, randomized, placebo-controlled study. Crit Care Med. 1996;24:207-214.
57. Jacobson JM, Greenspan JS, Spritzler J, et al; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997;336:1487-1493.